Elvina Almuradova: PTC significantly prolongs OS in patients with HER2+ metastatic breast cancer

Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on LinkedIn about a recent paper by Yutaka Yamamoto et al. published in Journal of Clinical Oncology:

“PRECIOUS Study: Pertuzumab Retreatment Improves Overall Survival in HER2+ Metastatic Breast Cancer.

New findings from the PRECIOUS trial reveal that pertuzumab + trastuzumab + chemotherapy (PTC) significantly prolongs overall survival (OS) in patients with HER2-positive metastatic breast cancer (mBC) who were previously treated with pertuzumab-containing regimens.

Key Results:

• Overall Survival (OS): 36.2 months (PTC) vs. 26.5 months (TC)
• Progression-Free Survival (PFS, investigator-assessed): 5.5 months (PTC) vs. 4.2 months (TC)

Dual HER2 blockade with pertuzumab + trastuzumab may provide a survival benefit even after prior pertuzumab treatment.”

“Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis”

Authors: Yutaka Yamamoto et al.

More posts featuring Elvina Almuradova.